Network meta-analysis of sacubitril/valsartan for the treatment of essential hypertension

AIM: Sacubitril/valsartan has been demonstrated to reduce blood pressure in hypertensive patients, but the best dose remains unclear. We performed this network meta-analysis to determine the comparative efficacy and safety of three available doses of sacubitril/valsartan (i.e., 100, 200, and 400 mg)...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yaling, Zhao, Xiaoyu, Huang, Hao, Li, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293449/
https://www.ncbi.nlm.nih.gov/pubmed/36326841
http://dx.doi.org/10.1007/s00392-022-02120-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293449/
https://www.ncbi.nlm.nih.gov/pubmed/36326841
http://dx.doi.org/10.1007/s00392-022-02120-0

Ejemplares similares